ClinicalTrials.gg
RecruitingNCT07262619Updated Oct 30, 2026

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

A Phase 1/2 interventional study of EIK1005 and pembrolizumab (KEYTRUDA® ) in Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors and MSI-H/dMMR Gastric Cancer, sponsored by Eikon Therapeutics. Recruiting at 45 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Eikon Therapeutics · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Oct 30, 2026First site in France10 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 715 studies in Endometrial Neoplasms with a site in United States — 197 open to participants now, 287 under way, 22 of them phase 3. Endometrial Neoplasms · United States.

Planned enrollment
156th of 591
160 · median 60
Started
2026
with 45 others
Phase 1/2
85 of 715
43 open now
Primary completion
2029-03
later than 239 of 286 live
Registered
668th of 715
by date

Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 156th largest by planned enrollment of the 591 interventional ones that give a count, is one of 46 that started in 2026, is one of 85 in phase 1/2, reaches primary completion later than 239 of the 286 other live ones, and was the 668th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

197 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:

192 more — sign in →

All 197 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 715 studies in Endometrial Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.

Read the detailed description

This Phase 1/2 study (EIK1005-002) will investigate the safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of EIK1005 as a monotherapy and in combination with pembrolizumab in participants with advanced solid tumors, including participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors.

The study will be conducted in 2 parts: Part 1 and Part 2, with Part 1 being further divided into Part 1A and Part 1B as described below:

  • Part 1A (monotherapy dose escalation): participants will receive EIK1005 only.
  • Part 1B (combination dose escalation): participants will receive EIK1005 in combination with pembrolizumab.
  • Part 2 (dose optimization): participants will be randomized 1:1 to monotherapy with EIK1005 at one of the two selected doses from Part 1A to identify the dose of EIK1005 in monotherapy for subsequent studies.
03

Conditions studied

  • Advanced Solid Tumors
  • MSI-H or dMMR Advanced Solid Tumors
  • MSI-H/dMMR Gastric Cancer
  • MSI-H/dMMR Colorectal Cancer
  • MSI-H/dMMR Gastroesophageal-junction Cancer
  • Endometrial Cancer
  • Mismatch Repair Deficient or MSI-High Solid Tumors

Keywords

  • Werner helicase
  • WRN
  • MSI-H
  • dMMR
  • DNA mismatch repair
  • EIK1005
  • Advanced Solid Tumors
  • Metastatic
  • MSI-H/dMMR Endometrial Cancer
  • MSI-H/dMMR Prostate Cancer
  • Pembrolizumab
  • Mismatch Repair Deficient (dMMR)
  • Microsatellite Instability High (MSI-H)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. is ≥ 18 years of age at the time of signing the .
  2. has a of at least 3 months.
  3. has or cytologically documented advanced (unresectable and/or ) solid tumor. Part 1A: recommend that participants have not more than 3 years old. Part 1B and Part 2: participant has locally confirmed Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) tumor. Participant must have archival tumor tissue (not more than 3 years old) for retrospective confirmation of MSI-H or dMMR tumor by a central laboratory.
  4. In Part 1A, has received and then progressed after or is intolerant to at least 1 standard treatment regimen in the advanced setting. The participant does not have alternative therapeutic options per PI's medical judgement. Preference should be given to: (1) participants with MSI-H or dMMR cancers that have progressed after (CPI) therapy and (2) participants with microsatellite stable cells (MSS) cancers that have progressed following at least one regimen of platinum, alkylating or topoisomerase containing chemotherapy.
  5. has at baseline according to version 1.1 (RECIST 1.1) as determined by the PI.
  6. has an (ECOG) score of 0 to 1.
  7. has an adequate organ and marrow function.

Key Exclusion Criteria:

  1. has not recovered (i.e., to Grade ≤ 1 or to baseline) from prior anti-cancer therapy-induced adverse events (AEs).
  2. has received prior treatment with Werner (WRN) inhibitor.
  3. has a history of relevant drug , ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients, history of serious allergic reactions leading to hospitalization, or any other allergic reaction in general.
  4. In Parts 1B and Part 2 Rescue: diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of study intervention.
  5. has known additional that is progressing or has required active treatment within the past 3 years.
  6. has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study treatment.
  7. has mean resting > 470 ms (men and women) obtained from triplicate (ECGs).
  8. has active disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Participants may enroll with the following conditions: Type 1 diabetes, hypothyroidism requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia not requiring systemic treatment).
  9. has history of (non-infectious) pneumonitis/pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
  10. has active tuberculosis.
  11. has any active infections requiring systemic therapy.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Part 1A (Dose escalation, Monotherapy)

    EIK1005 will be given as monotherapy in participants without alternative treatment options.

    Drug: EIK1005

  • Experimental
    Part 1B (Dose escalation, Combination with pembrolizumab)

    EIK1005 will be given in combination with pembrolizumab to participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) solid tumors.

    Drug: EIK1005 · Drug: pembrolizumab (KEYTRUDA® )

  • Experimental
    Part 2 (Dose optimization, Monotherapy)

    Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) advanced solid tumors will be randomized to receive EIK1005 monotherapy at one of the two identified doses selected from Part 1A.

    Drug: EIK1005

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity (DLT) - Part 1

    A DLT is a protocol-defined adverse event occurring during the DLT observation period.

    Time frame: 21 Days

  2. Adverse Events (AEs) - Part 1 and Part 2

    Number of participants reporting adverse events or serious adverse events.

    Time frame: From the time of first dose of study medication through 30 days following cessation of study treatment.

Secondary outcomes

  1. Objective Response (OR) - Part 1 and Part 2

    OR defined as participants who have a complete response \[CR\] or partial response \[PR\] by Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1 as assessed by the Investigator.

    Time frame: Through study completion, an average of 2 years.

  2. Duration of Response (DOR) - Part 1 and Part 2

    DOR (defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR) by RECIST 1.1 as assessed by the Investigator.

    Time frame: Through study completion, an average of 2 years.

  3. Disease Control (DC) - Part 1 and Part 2

    DC defined as participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) by RECIST 1.1 as assessed by the Investigator.

    Time frame: Through study completion, an average of 2 years.

  4. Progression-free survival (PFS) - Part 2

    PFS defined as the time from randomization to the first documented disease progression by RECIST 1.1 as assessed by the Investigator or death due to any cause, whichever occurs first.

    Time frame: Through study completion, an average of 2 years.

  5. Pharmacokinetic (PK) parameters of EIK1005 - AUC0-24 (Part 1 and Part 2)

    AUC0-24 (Area Under the plasma Concentration versus time curve from 0 to 24 hours): Measures total drug exposure over the first 24 hours after dosing of EIK1005 as monotherapy and in combination with pembrolizumab.

    Time frame: Up to 1 year

  6. Pharmacokinetic (PK) parameters of EIK1005 - AUCtau,ss (Part 1 and Part 2)

    AUCtau,ss \[Area Under the plasma Concentration versus time curve over one dosing interval (tau) at steady state\]: Reflects average drug exposure during each dosing interval once the steady state has been reached for EIK1005 as monotherapy and in combination with pembrolizumab.

    Time frame: Up to 1 year

  7. Pharmacokinetic (PK) parameters of EIK1005 - Cmax (Part 1 and Part 2)

    Cmax (Maximum Plasma Concentration) after dose administration of EIK1005 as monotherapy and in combination with pembrolizumab.

    Time frame: Up to 1 year

  8. Pharmacokinetic (PK) parameters of EIK1005 - tmax (Part 1 and Part 2)

    tmax (the time required for the plasma concentration of the drug to reach maximum concentration after dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab.

    Time frame: Up to 1 year

  9. Pharmacokinetic (PK) parameters of EIK1005 - t½ (Half-life) (Part 1 and Part 2)

    Half-life (the time required for the plasma concentration of the drug to decrease by 50% after the dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab.

    Time frame: Up to 1 year

07

Study locations

44 of 45 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2029, 38 months after the start.

Of 80 phase 1/2 interventional studies under Endometrial Neoplasms, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 106. This study's planned 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2025
First posted
Dec 3, 2025
StartActual
Jan 20, 2026
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added — first site in France
Show 10 added (2 Germany, 2 Portugal, 2 South Korea, 2 Spain, 1 France, 1 Singapore)
  • Hospices Civils De Lyon (hcl) -Centre Hospitalier Lyon-Sud · Pierre-Bénite, France
  • DONAUISAR Klinikum · Deggendorf, Germany
  • Helios Klinikum Berlin-Buch · Berlin, Germany
  • Hospital da Luz Lisboa · Lisbon, Portugal
  • Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO Porto) · Porto, Portugal
  • National University Hospital (NUH) · Singapore, Singapore
  • Inje University-Haeundae Paik Hospital · Busan, South Korea
  • Korea University Anam Hospital · Seoul, South Korea
  • Hospital Universitari Son Espases · Palma, Spain
  • Hospital Clinic Barcelona · Barcelona, Spain
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    10 sites added — first site in France
    Show 10 added (2 Germany, 2 Portugal, 2 South Korea, 2 Spain, 1 France, 1 Singapore)
    • Hospices Civils De Lyon (hcl) -Centre Hospitalier Lyon-Sud · Pierre-Bénite, France
    • DONAUISAR Klinikum · Deggendorf, Germany
    • Helios Klinikum Berlin-Buch · Berlin, Germany
    • Hospital da Luz Lisboa · Lisbon, Portugal
    • Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO Porto) · Porto, Portugal
    • National University Hospital (NUH) · Singapore, Singapore
    • Inje University-Haeundae Paik Hospital · Busan, South Korea
    • Korea University Anam Hospital · Seoul, South Korea
    • Hospital Universitari Son Espases · Palma, Spain
    • Hospital Clinic Barcelona · Barcelona, Spain

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07262619
Lead sponsor
Eikon Therapeutics
Responsible party
Sponsor
First posted
Dec 3, 2025
Start date
Jan 20, 2026
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Ana C Mamede, PharmD
Contact
mamedea@eikontx.com
347-806-4584
Krishna Kaza
Contact
kazak@eikontx.com
Nilou Mobashery, MD
study director · Eikon Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion